Denali Therapeutics
DNLI
DNLI
170 hedge funds and large institutions have $2.96B invested in Denali Therapeutics in 2020 Q3 according to their latest regulatory filings, with 42 funds opening new positions, 54 increasing their positions, 48 reducing their positions, and 20 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more capital invested
Capital invested by funds: $ → $
more funds holding in top 10
Funds holding in top 10: →
more funds holding
Funds holding: →
13% more repeat investments, than reductions
Existing positions increased: 54 | Existing positions reduced: 48
0.26% less ownership
Funds ownership: 78.36% → 78.09% (-0.26%)
18% less call options, than puts
Call options by funds: $2.08M | Put options by funds: $2.55M
Holders
170
Holding in Top 10
4
Calls
$2.08M
Puts
$2.55M
Top Buyers
| 1 | +$62.3M | |
| 2 | +$55.5M | |
| 3 | +$12.3M | |
| 4 |
Marshall Wace
London,
United Kingdom
|
+$10.3M |
| 5 |
Goldman Sachs
New York
|
+$9.95M |
Top Sellers
| 1 | -$71.7M | |
| 2 | -$51.7M | |
| 3 | -$17.9M | |
| 4 |
EC
EcoR1 Capital
San Francisco,
California
|
-$17.7M |
| 5 |
MWNA
Marshall Wace North America
New York
|
-$14.1M |